Novo reports positive Phase III REDEFINE 1 results for CagriSema
The post hoc assessment showed that 67.8% of participants receiving CagriSema achieved early responder status by week eight.
The post hoc assessment showed that 67.8% of participants receiving CagriSema achieved early responder status by week eight.
Research strength, clinical capabilities, favourable regulatory policies and direct access to the Greater Bay Area are expanding Hong Kong’s value to medical-device companies, with HKSTP’s first MEDICA pavilion providing fresh...
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
Australia starts investigation into OpenAI Medicare breach
Industry partnership will determine the success of the transition to low-GWP pMDIs
TrialAssure selected as EMA’s official clinical trial anonymisation partner
ASCO26: AI innovations show promise in reducing the oncology RWD burden